首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial.
【24h】

Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial.

机译:纤维蛋白鞘剥离与导管更换治疗失败的隧道式血液透析导管:随机临床试验。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To compare the effectiveness of two treatments for tunneled hemodialysis catheter malfunction: percutaneous fibrin sheath stripping (PFSS) and over-the-wire catheter exchange (EX). MATERIALS AND METHODS: Adult patients with poorly functioning tunneled hemodialysis catheters (flow rates < 200 mL/min) were randomly assigned to receive either PFSS or EX. Over the course of 20 months, 30 patients (37 encounters) referred to a single institution met the inclusion criteria and consented to participate. PFSS employed transcatheter snares via femoral vein puncture, whereas EX was performed over a guide wire with use of fluoroscopic guidance. Patients were followed up to determine the duration of continued adequate hemodialysis via manipulated catheters for up to 4 months (primary outcome measure). RESULTS: Overall technical success rate was 97%. Mean catheter patency for the PFSS group was 24.5 +/- 29.3 days, and 52.2 +/- 43 days for the EX group (P < .0001). After EX, patency rates at 1, 2, 3, and 4 months were 71%, 33%, 27%, and 27%, compared to 31%, 16%, 7%, and 0% after PFSS (P = .04, logrank test). Exchanged catheters were significantly more likely to be patent for as long as 4 months (23% versus 0%; P < .05, chi2 test). CONCLUSIONS: Malfunctioning tunneled hemodialysis catheters treated by means of EX are significantly more likely to remain patent for up to 4 months than are those treated by means of PFSS. According to the results of this trial, PFSS should not be performed as a routine therapy for catheter malfunction.
机译:目的:为了比较两种治疗隧道性血液透析导管故障的有效性:经皮纤维蛋白护套剥除术(PFSS)和线控导管置换术(EX)。材料与方法:随机分配成年患者,其功能不佳的隧道血液透析导管(流速<200 mL / min)接受PFSS或EX。在20个月的过程中,转诊至单个机构的30名患者(37次遭遇)符合纳入标准并同意参加。 PFSS通过股静脉穿刺采用经导管圈套器,而EX是使用荧光镜引导在导丝上进行的。对患者进行随访,以确定通过操纵的导管持续进行足够的血液透析的持续时间,最长可达4个月(主要结局指标)。结果:总体技术成功率为97%。 PFSS组的平均导管通畅时间为24.5 +/- 29.3天,EX组为52.2 +/- 43天(P <.0001)。在EX后,在1、2、3和4个月时的通畅率分别为71%,33%,27%和27%,而PFSS后的通畅率为31%,16%,7%和0%(P = .04 ,logrank测试)。更换导管在长达4个月的时间里更有可能获得专利(23%比0%; P <.05,chi2测试)。结论:与PFSS相比,用EX进行治疗的功能不正常的隧道式血液透析导管在长达4个月的时间内仍可能保持专利。根据该试验的结果,PFSS不应作为导管故障的常规治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号